Home › Chronic Lymphocytic Leukemia › California › San Francisco
Chronic Lymphocytic Leukemia clinical trials in San Francisco, CA
4 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 3
- Kaiser Permanente San Francisco Medical Center Oncology, San Francisco
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- University of California, San Francisco, San Francisco
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
RecruitingPhase 1
- University of California, San Francisco, San Francisco
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RecruitingPhase 2
- San Francisco VA Medical Center, San Francisco, CA, San Francisco
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA32 studies
- Columbus, OH29 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA21 studies
- Rochester, MN19 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI14 studies
- Cincinnati, OH14 studies
- Chicago, IL14 studies
Other studies in San Francisco
- Prostate Cancer45 studies
- Breast Cancer43 studies
- Non-Small Cell Lung Cancer37 studies
- Cancer (all types)35 studies
- Heart Failure29 studies
- Metastatic Cancer29 studies
- Lung Cancer23 studies
- Melanoma22 studies
- Pancreatic Cancer20 studies
- Colorectal Cancer19 studies
- Cardiovascular Disease18 studies
- Ovarian Cancer18 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.